FDA Drug Recalls

Recalls / Class II

Class IID-0637-2022

Product

Moxifloxacin Ophthalmic Solution USP 0.5%, 3 mL, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Dist. By Aurobindo Pharma USA, Inc. East Windsor, NJ 08520, NDC 72189-076-05

Affected lot / code info
Lot#: 18JA2218 Exp. 6/30/23; 20DE2104 Exp. 6/30/23; 08NO2111 Exp. 6/30/23

Why it was recalled

Failed impurities/degradation specifications

Recalling firm

Firm
Direct Rx
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
94 Worldwide Dr, Dawsonville, Georgia 30534-6828

Distribution

Quantity
44 bottles
Distribution pattern
Florida

Timeline

Recall initiated
2022-02-17
FDA classified
2022-02-25
Posted by FDA
2022-03-09
Terminated
2023-10-04
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0637-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: drug · FDA Drug Recalls